BIOFRONTERA AG (B8FK.DE) Stock Fundamental Analysis
Europe - FRA:B8FK - DE000A4BGGM7 - Common Stock
2.67 EUR
0 (0%)
We assign a fundamental rating of 2 out of 10 to B8FK. B8FK was compared to 52 industry peers in the Pharmaceuticals industry. B8FK scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. B8FK has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year B8FK has reported negative net income.
B8FK had a positive operating cash flow in the past year.
B8FK had negative earnings in 4 of the past 5 years.
B8FK had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -12.27%, B8FK is doing worse than 75.47% of the companies in the same industry.
B8FK's Return On Equity of -18.00% is on the low side compared to the rest of the industry. B8FK is outperformed by 73.58% of its industry peers.
B8FK has a Return On Invested Capital of 0.59%. This is in the lower half of the industry: B8FK underperforms 66.04% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -12.27% | ||
| ROE | -18% | ||
| ROIC | 0.59% |
ROA(3y)-50.22%
ROA(5y)N/A
ROE(3y)-80.64%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Operating Margin, with a value of 0.56%, B8FK is doing worse than 66.04% of the companies in the same industry.
With an excellent Gross Margin value of 78.43%, B8FK belongs to the best of the industry, outperforming 81.13% of the companies in the same industry.
In the last couple of years the Gross Margin of B8FK has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 0.56% | ||
| PM (TTM) | N/A | ||
| GM | 78.43% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.43%
GM growth 5YN/A
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), B8FK is destroying value.
B8FK has more shares outstanding than it did 1 year ago.
The debt/assets ratio for B8FK has been reduced compared to a year ago.
2.2 Solvency
B8FK has an Altman-Z score of -5.07. This is a bad value and indicates that B8FK is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -5.07, B8FK is not doing good in the industry: 81.13% of the companies in the same industry are doing better.
B8FK has a debt to FCF ratio of 0.33. This is a very positive value and a sign of high solvency as it would only need 0.33 years to pay back of all of its debts.
With an excellent Debt to FCF ratio value of 0.33, B8FK belongs to the best of the industry, outperforming 98.11% of the companies in the same industry.
B8FK has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of B8FK (0.01) is better than 92.45% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.33 | ||
| Altman-Z | -5.07 |
ROIC/WACC0.08
WACC7.12%
2.3 Liquidity
A Current Ratio of 2.47 indicates that B8FK has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.47, B8FK belongs to the top of the industry, outperforming 83.02% of the companies in the same industry.
A Quick Ratio of 1.81 indicates that B8FK should not have too much problems paying its short term obligations.
B8FK has a better Quick ratio (1.81) than 84.91% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.47 | ||
| Quick Ratio | 1.81 |
3. Growth
3.1 Past
B8FK shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -8.46%.
B8FK shows a small growth in Revenue. In the last year, the Revenue has grown by 7.14%.
The Revenue has been decreasing by -9.04% on average over the past years.
EPS 1Y (TTM)-8.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-82.5%
Revenue 1Y (TTM)7.14%
Revenue growth 3Y-9.04%
Revenue growth 5YN/A
Sales Q2Q%-14.4%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y124.55%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year22.18%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
B8FK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 24.37, B8FK is valued on the expensive side.
Based on the Price/Forward Earnings ratio, B8FK is valued a bit more expensive than 64.15% of the companies in the same industry.
B8FK is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 22.99, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 24.37 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of B8FK is on the same level as its industry peers.
B8FK's Price/Free Cash Flow ratio is rather cheap when compared to the industry. B8FK is cheaper than 88.68% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 9.96 | ||
| EV/EBITDA | 15.39 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for B8FK!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:B8FK (10/24/2025, 7:00:00 PM)
2.67
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners12.23%
Ins Owner ChangeN/A
Market Cap16.23M
Revenue(TTM)23.22M
Net Income(TTM)-2700000
Analysts82.86
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 24.37 | ||
| P/S | 0.7 | ||
| P/FCF | 9.96 | ||
| P/OCF | 8.73 | ||
| P/B | 1.05 | ||
| P/tB | 1.05 | ||
| EV/EBITDA | 15.39 |
EPS(TTM)-0.45
EYN/A
EPS(NY)0.11
Fwd EY4.1%
FCF(TTM)0.27
FCFY10.04%
OCF(TTM)0.31
OCFY11.46%
SpS3.82
BVpS2.53
TBVpS2.53
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -12.27% | ||
| ROE | -18% | ||
| ROCE | 0.84% | ||
| ROIC | 0.59% | ||
| ROICexc | 0.59% | ||
| ROICexgc | 0.59% | ||
| OM | 0.56% | ||
| PM (TTM) | N/A | ||
| GM | 78.43% | ||
| FCFM | 7.02% |
ROA(3y)-50.22%
ROA(5y)N/A
ROE(3y)-80.64%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.43%
GM growth 5YN/A
F-Score6
Asset Turnover1.06
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.33 | ||
| Debt/EBITDA | 0.11 | ||
| Cap/Depr | 23.96% | ||
| Cap/Sales | 0.99% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 170.64% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.47 | ||
| Quick Ratio | 1.81 | ||
| Altman-Z | -5.07 |
F-Score6
WACC7.12%
ROIC/WACC0.08
Cap/Depr(3y)90.56%
Cap/Depr(5y)N/A
Cap/Sales(3y)2.53%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-8.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-82.5%
EPS Next Y124.55%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)7.14%
Revenue growth 3Y-9.04%
Revenue growth 5YN/A
Sales Q2Q%-14.4%
Revenue Next Year22.18%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y105.94%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year131.82%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y2.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-32.98%
OCF growth 3YN/A
OCF growth 5YN/A
BIOFRONTERA AG / B8FK.DE FAQ
What is the ChartMill fundamental rating of BIOFRONTERA AG (B8FK.DE) stock?
ChartMill assigns a fundamental rating of 2 / 10 to B8FK.DE.
What is the valuation status for B8FK stock?
ChartMill assigns a valuation rating of 3 / 10 to BIOFRONTERA AG (B8FK.DE). This can be considered as Overvalued.
What is the profitability of B8FK stock?
BIOFRONTERA AG (B8FK.DE) has a profitability rating of 1 / 10.
Can you provide the financial health for B8FK stock?
The financial health rating of BIOFRONTERA AG (B8FK.DE) is 6 / 10.